ATE493141T1 - Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns - Google Patents

Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns

Info

Publication number
ATE493141T1
ATE493141T1 AT03010945T AT03010945T ATE493141T1 AT E493141 T1 ATE493141 T1 AT E493141T1 AT 03010945 T AT03010945 T AT 03010945T AT 03010945 T AT03010945 T AT 03010945T AT E493141 T1 ATE493141 T1 AT E493141T1
Authority
AT
Austria
Prior art keywords
morphogens
nervous system
central nervous
morphogen
ischemia
Prior art date
Application number
AT03010945T
Other languages
German (de)
English (en)
Inventor
Marc F Charette
Seth P Finklestein
Original Assignee
Stryker Corp
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24485972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE493141(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stryker Corp, Gen Hospital Corp filed Critical Stryker Corp
Application granted granted Critical
Publication of ATE493141T1 publication Critical patent/ATE493141T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of Electric Motors In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Protection Of Generators And Motors (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
AT03010945T 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns ATE493141T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62044496A 1996-03-22 1996-03-22

Publications (1)

Publication Number Publication Date
ATE493141T1 true ATE493141T1 (de) 2011-01-15

Family

ID=24485972

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03010945T ATE493141T1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
AT97917532T ATE244574T1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97917532T ATE244574T1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns

Country Status (11)

Country Link
US (4) US6407060B1 (enExample)
EP (3) EP1364655B1 (enExample)
JP (2) JP2000507939A (enExample)
KR (1) KR20000064752A (enExample)
CN (1) CN1181885C (enExample)
AT (2) ATE493141T1 (enExample)
AU (2) AU725341B2 (enExample)
CA (2) CA2249368A1 (enExample)
DE (2) DE69740089D1 (enExample)
ES (1) ES2201287T5 (enExample)
WO (2) WO1997034618A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
DE69433530T2 (de) 1993-05-12 2005-01-05 Genetics Institute, LLC, Cambridge Bmp-11 zusammensetzungen
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
PT733109E (pt) 1993-12-07 2006-07-31 Genetics Inst Llc Proteinas morfogeneticas dos 0ss0s pmo-12 e pmo-13 e as suas composicoes para inducao de tendao
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
WO1998020889A1 (en) * 1996-11-15 1998-05-22 Creative Biomolecules Inc Morphogen peptide-induced regeneration of sense perceptory tissues
EP0980252B1 (en) 1997-05-05 2004-10-06 Curis, Inc. Therapies for acute renal failure
EP0985149A1 (en) * 1997-05-30 2000-03-15 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
WO1999028341A2 (en) * 1997-12-04 1999-06-10 Creative Biomolecules, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
DE19837230A1 (de) * 1998-08-17 2000-03-09 Jean Krutmann Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
AU6790300A (en) * 1999-08-18 2001-03-13 Children's Medical Center Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
AU774427B2 (en) 1999-10-15 2004-06-24 Fidia Advanced Biopolymers S.R.L. Formulations of hyaluronic acid for delivery of osteogenic proteins
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
CA2411666A1 (en) 2000-06-01 2001-12-06 Children's Medical Center Corporation Methods and compositions for producing a neurosalutary effect in a subject
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
CA2449008A1 (en) 2001-06-01 2002-12-12 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
JP2004528042A (ja) * 2001-06-01 2004-09-16 エクサイト セラピーズ， インコーポレイテッド Ｔ細胞誘導性組織修復および再生
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20060259014A1 (en) 2002-05-22 2006-11-16 Surgimark, Inc. Aspirator sleeve and suction handle
BR0316560A (pt) 2002-11-26 2005-10-04 Nobex Corp Conjugado de composto natriurético, formulação farmacêutica, método de tratar uma condição, método de preparação do conjugado de composto natriurético, conjugado de peptìdeo pró-polinatriurético modificado, análogo de peptìdeo natriurético, análogo de hbnp, composto, e, método de preparar um composto
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
EP1623017B1 (en) 2003-05-08 2010-09-15 Life Technologies Corporation Generation and isolation of antigen-specific t cells
EP2789342A1 (en) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
DK2453024T3 (en) 2004-06-21 2018-02-12 Univ Leland Stanford Junior Genes and conduits that are differentially expressed in bipolar disorder and / or major depressive disorder
WO2006012365A2 (en) * 2004-07-20 2006-02-02 University Of Maryland Protease inhibitor
EP1782821A4 (en) * 2004-07-29 2009-11-11 Anges Mg Inc MEDICAMENT AND METHOD FOR IMPROVING BRAIN FUNCTION
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
US8299212B2 (en) 2005-09-20 2012-10-30 Thrasos Therapeutics, Inc. TDF-related compounds and analogs thereof, analogs and bioactive fragments
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
HRP20120698T1 (hr) * 2007-01-25 2013-09-30 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Uporaba dgf-5 za poboljšanje ili održavanje izgleda kože
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
WO2009129101A1 (en) * 2008-04-14 2009-10-22 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
EP2396026A2 (en) * 2009-02-12 2011-12-21 Stryker Corporation Compositions and methods for minimally-invasive systemic delivery of proteins including tgf- superfamily members
CN102369016A (zh) * 2009-02-12 2012-03-07 史赛克公司 用于治疗系统性病症和疾病的包含TGF-β超家族成员的蛋白质的外周施用
EP2406281B1 (en) 2009-03-12 2016-02-17 Haase Investments UG Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
CA2774024A1 (en) 2009-09-17 2011-03-24 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
JP2013514811A (ja) 2009-12-22 2013-05-02 ストライカー コーポレイション 免疫原性が抑制されたｂｍｐ−７変異体
CN101822815A (zh) * 2010-04-29 2010-09-08 广东八加一医药有限公司 系列多肽小分子在制备防治缺血性脑血管疾病药物中的应用
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
CA2807343C (en) 2010-08-20 2018-05-22 Wyeth Llc Designer osteogenic proteins
AU2012225784B2 (en) * 2011-03-04 2016-03-17 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
KR101274930B1 (ko) * 2011-06-03 2013-06-17 전남대학교산학협력단 골 형성 또는 혈관신생 촉진용 펩타이드 ｂｆｐ 4 및 이의 용도
WO2013013085A2 (en) * 2011-07-19 2013-01-24 Thrasos Innovation, Inc. Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
WO2014201143A1 (en) * 2013-06-11 2014-12-18 President And Fellows Of Harvard College Methods and compositions for increasing neurogenesis and angiogenesis
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
JP2019528284A (ja) 2016-08-17 2019-10-10 ファクター バイオサイエンス インコーポレイテッド 核酸産物およびその投与方法
JP2021529835A (ja) * 2018-07-03 2021-11-04 ベンチュリス セラピューティクス， インク．Ｖｅｎｔｕｒｉｓ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 脳卒中を治療するための組成物及び方法
EP4528281A3 (en) * 2020-02-20 2025-06-18 Universiteit Maastricht Detection method of circulating bmp10 (bone morphogenetic protein 10)
EP4154001A4 (en) * 2020-05-19 2024-06-05 Elevian, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE
WO2024259004A1 (en) * 2023-06-13 2024-12-19 Bedford Research Foundation Systems and methods of cell transport at ambient temperature

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440860A (en) 1980-01-18 1984-04-03 The Children's Medical Center Corporation Stimulating cell growth
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4296100A (en) 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
DE3110560A1 (de) 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
US4971952A (en) 1986-03-06 1990-11-20 Collagen Corporation Method of treating inflammation with cartilage inducing factor
US4806523A (en) 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4994559A (en) 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1322714C (en) 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
EP0269408A3 (en) 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
US4797277A (en) 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5108753A (en) 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
JPH0262829A (ja) 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
US4983581A (en) 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
HU201095B (en) 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
WO1990000619A1 (en) 1988-07-08 1990-01-25 University College London Analysis of cell modifying substances
AU4056089A (en) 1988-07-20 1990-02-19 Amgen, Inc. Method of treating inflammatory disorders by reducing phagocyte activation
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5002965A (en) 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
US5118791A (en) 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
IL97365A0 (en) 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
US5158934A (en) 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
DE69032424T2 (de) 1989-10-17 1999-02-04 Stryker Corp., Kalamazoo, Mich. Osteogene vorrichtungen
US5108989A (en) 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
WO1992000382A1 (en) 1990-06-15 1992-01-09 Carnegie Institution Of Washington Gdf-1
DE69133338T2 (de) 1990-09-26 2004-04-15 Genetics Institute, LLC, Cambridge Bmp-5-derivate
WO1992007073A1 (en) 1990-10-18 1992-04-30 Creative Biomolecules, Inc. Osteogenic peptides
DE69132275T2 (de) 1990-11-16 2001-01-25 Celtrix Pharmaceuticals, Inc. Beta-type ähnlicher transformierender wachstumfaktor
EP1142581A3 (en) 1990-11-27 2002-09-11 American National Red Cross Tissue sealant and growth factor containing compositions that promote accelerated wound healing
AU651421B2 (en) 1990-11-30 1994-07-21 Celtrix Pharmaceuticals, Inc. Use of a bone morphogenetic protein in synergistic combination with TGF-beta for bone repair
DE69231946T2 (de) * 1991-03-11 2002-04-04 Curis, Inc. Protein-induzierende morphogenese
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
JPH06500574A (ja) 1991-05-10 1994-01-20 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ アクチビン／ＴＧＦ―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
JPH07500315A (ja) 1991-05-10 1995-01-12 セルトリックス　ファーマシューティカルズ，インコーポレイテッド 骨成長因子の標的送達
ES2094359T3 (es) 1991-06-21 1997-01-16 Genetics Inst Formulaciones farmaceuticas de proteinas osteogenicas.
ATE175441T1 (de) 1991-06-25 1999-01-15 Genetics Inst Bmp-9 zusammensetzungen
CA2116562C (en) * 1991-08-30 1999-04-13 Thangavel Kuberasampath Morphogen-induced modulation of inflammatory response
EP0825442A3 (en) 1991-08-30 2004-02-11 Curis, Inc. Morphogenic protein screening method
JP4235689B2 (ja) 1991-08-30 2009-03-11 ストライカー・コーポレーション 骨疾患を処置するための骨形成タンパク質
WO1993009229A1 (en) 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
WO1993008828A1 (en) * 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
JP4101284B2 (ja) * 1991-11-22 2008-06-18 ジェネンテック・インコーポレーテッド 神経損傷を改善するｔｇｆ−ｂｅｔａ
DE19525416A1 (de) † 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
JP4344012B2 (ja) 1992-07-31 2009-10-14 ストライカー・コーポレーション 組織形成因子誘導による神経の再生と修復
ES2061380B1 (es) * 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
CA2169191C (en) 1993-08-26 2008-01-15 Elizabeth A. Wang Neural regeneration using human bone morphogenetic proteins
WO1995006656A1 (en) 1993-09-03 1995-03-09 The Regents Of The University Of California Neural tissue affecting factor and compositions
ATE355369T1 (de) 1993-10-14 2006-03-15 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
WO1995024474A1 (en) 1994-03-10 1995-09-14 Human Genome Sciences, Inc. Bone morphogenic protein-10
WO1998020889A1 (en) * 1996-11-15 1998-05-22 Creative Biomolecules Inc Morphogen peptide-induced regeneration of sense perceptory tissues

Also Published As

Publication number Publication date
AU725341B2 (en) 2000-10-12
ES2201287T5 (es) 2007-10-16
KR20000064752A (ko) 2000-11-06
WO1997034626A1 (en) 1997-09-25
CA2249596A1 (en) 1997-09-25
US20010039261A1 (en) 2001-11-08
EP0894004B1 (en) 2003-07-09
US20030022830A1 (en) 2003-01-30
AU2582397A (en) 1997-10-10
US6214796B1 (en) 2001-04-10
DE69723429T2 (de) 2004-04-22
DE69723429D1 (de) 2003-08-14
JP2000506894A (ja) 2000-06-06
CN1219133A (zh) 1999-06-09
DE69723429T3 (de) 2007-09-20
ATE244574T1 (de) 2003-07-15
CA2249368A1 (en) 1997-09-25
US6407060B1 (en) 2002-06-18
CN1181885C (zh) 2004-12-29
EP0904093A1 (en) 1999-03-31
WO1997034618A1 (en) 1997-09-25
ES2201287T3 (es) 2004-03-16
AU2552997A (en) 1997-10-10
AU734312B2 (en) 2001-06-07
JP4847634B2 (ja) 2011-12-28
EP1364655B1 (en) 2010-12-29
DE69740089D1 (de) 2011-02-10
EP1364655A1 (en) 2003-11-26
EP0904093A4 (en) 2004-11-17
CA2249596C (en) 2011-11-08
EP0894004B2 (en) 2007-02-21
EP0894004A1 (en) 1999-02-03
JP2000507939A (ja) 2000-06-27

Similar Documents

Publication Publication Date Title
ATE493141T1 (de) Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
DE3587266D1 (de) Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut.
DE69532482D1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda-antagonisten enthält
MY111188A (en) Improvements in or relating to benzothiophenes.
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
ATE293883T1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
DE69232287D1 (de) Verfahren und zusammensetzung zur verminderung von reperfusionsschäden des myokards
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
IL91322A0 (en) Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract
DE3878627D1 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
ATE526980T1 (de) Zusammensetzungen und verfahren zur heilung von nervengeweben
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
EP0515434A4 (en) Method for treating intestinal diseases
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
ATE118350T1 (de) Zusammensetzungen und verfahren zur behandlung von hautkrankheiten und zur aktivierung der wundheilung.
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
ZA9010080B (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
BG102716A (en) Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline
ATE167628T1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
PH24094A (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
Baines et al. Selective activity of a proctolin analogue reveals the existence of two receptor subtypes
UA39179C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, спосіб її одержання та антиаритмічний лікарський засіб

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties